首页> 外文期刊>Antiviral Research >Dynamics of hepatitis B virus resistance to entecavir in a nucleosideucleotide-naive patient.
【24h】

Dynamics of hepatitis B virus resistance to entecavir in a nucleosideucleotide-naive patient.

机译:乙型/核苷酸初治患者乙型肝炎病毒对恩替卡韦耐药性的变化。

获取原文
获取原文并翻译 | 示例
       

摘要

The genotypic evolution of HBV quasi-species was analyzed in a nucleosideucleotide-naive patient who developed resistance to entecavir. The lamivudine resistant quasi-species (rtM204V+/-rtL180M), absent at baseline, were emerged as early as 48 weeks after entecavir administration. Entecavir-resistant quasi-species (rtM204V+/-rtL180M plus S202G) were found after week 112 and gradually became the predominant mutations afterwards. The lamivudine- and entecavir-resistant mutations emerged closely in combination with the rtV207L, rtA222T, rtP237T or rtI163V substitutions. Our results indicated that the lamivudine-resistant mutations were developed first and may serve as a prequisite for subsequent entecavir-resistant mutations in this nucleosideucleotide-naive patient.
机译:在对恩替卡韦产生抗药性的无核苷/无核苷酸的患者中分析了HBV准种的基因型进化。拉米夫定耐药性准种(rtM204V +/- rtL180M),在基线时不存在,最早在恩替卡韦给药后48周出现。在第112周后发现耐恩替卡韦的准种(rtM204V +/- rtL180M加S202G),此后逐渐成为主要的突变。拉米夫定和恩替卡韦耐药性突变与rtV207L,rtA222T,rtP237T或rtI163V取代密切相关。我们的结果表明,拉米夫定耐药性突变首先被开发出来,并且可能是该核苷/未使用过核苷酸的患者随后接受恩替卡韦耐药性突变的前提。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号